Anti-CD20 monoclonal antibody in the treatment of pemphigus vulgaris
- Author:
- No author available
- Journal Title:
- International Journal of Dermatology and Venereology
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1673-4173.2017.06.002
- Key Word:
- 天疱疮;抗体,单克隆;治疗应用;抗CD20;利妥昔单抗;Pemphigus;Antibodies,monoclonal;Therapeutic uses;Anti CD20;Rituximab
Abstract： Pemphigus vulgaris is a kind of autoimmune skin disease involving the skin and mucous membranes and characterized by generalized blisters.Medicines exert their therapeutic effect on pemphigus vulgaris mainly by suppressing the immune system and reducing the production of related specific antibodies.At present,glucocorticoids still serve as the first-choice routine treatment.Rituximab,a kind of anti-CD20 monoclonal antibody,has shown satisfactory therapeutic effects in the adjuvant treatment of pemphigus vulgaris in recent years.However,the treatment with rituximab can cause severe transfusion-related reactions and increase the risk of infection.Because of the disadvantages of high price,long treatment duration,high recurrence risk and drug resistance,the clinical application of rituximab in the treatment of pemphigus vulgaris has been reduced.The new generation of anti-CD20 monoclonal antibody can overcome adverse reactions induced by rituximab treatment,improve medication approaches and reduce the treatment duration,so it has been gradually applied to the treatment of pemphigus vulgaris.In addition,new research results can provide more treatment options for patients with pemphigus vulgaris.
- [1]Rezvani AR,Maloney DG.Rituximab resistance.[J].2011,24(2).
- [2]Stamatis, Gregoriou,Ourania, Efthymiou,Christina, Stefanaki,etc.Management of pemphigus vulgaris: challenges and solutions.[J].2015,8.
- [3]Ahmed, A. Razzaque,Shetty, Shawn.A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab[J].2015,14(4).
- [4]Julia E. Graves,Kara Nunley,Michael P. Heffernan.Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)[J].2007,56(1).
- [5]Ahmed, A. Razzaque,Nguyen, Tegan,Kaveri, Srini,etc.First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up[J].2016,34.
- [6]Liebman, Howard A.,Saleh, Mansoor N.,Bussel, James B.,etc.Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia[J].2016,101(11).
- [7]Luisa Lunar don,Kathleen J. Tsai,Kathleen J. Propert,etc.Adjuvant Rituximab Therapy of Pemphigus A Single-Center Experience With 31 Patients[J].2012,148(9).
- [8]Hammers, Christoph M.,Chen, Jing,Lin, Chenyan,etc.Persistence of Anti-Desmoglein 3 IgG(+) B-Cell Clones in Pemphigus Patients over Years[J].2015,135(3).
- [9]Ellebrecht, Christoph T.,Choi, Eun J.,Allman, David M.,etc.Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris[J].2014,150(12).
- [10]Casulo,C.,Vose,J.M.,Ho,W.Y.,etc.A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics[J].2014,154(1).
- [11]Christoph T, Ellebrecht,Aimee S, Payne.Setting the target for pemphigus vulgaris therapy.[J].2017,2(5).
- [12]Christian Klein,Alfred Lammens,Wolfgang Schäfer,etc.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties[J].2013,5(1).
- [13]Avivi,I.,Stroopinsky,D.,Katz,T..Anti-CD20 monoclonal antibodies: Beyond B-cells[J].2013,27(5).
- [14]Eming R,Nagel A,Wolff-Franke S,etc.Rituximab exerts a dual effect in pemphigus vulgaris.[J].2008,128(12).
- [15]L.A. Butler,C.S. Tam,J.F. Seymour.Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era[J].2017,31(5).
- [16]Mossner E,Brunker P,Moser S,etc.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.[J].2010,115(22).
- [17]Forero-Torres,A.,DeVos,S.,Pohlman,B.L.,etc.Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma[J].2012,18(5).
- [18]Mitra M. Fatourechi,Rokea A. El‐Azhary,Lawrence E. Gibson.Rituximab: Applications in dermatology[J].2006,45(10).
- [19]Czuczman MS,Gregory SA.The future of CD20 monoclonal antibody therapy in B-cell malignancies.[J].2010,51(6).
- [20]Morschhauser F,Leonard JP,Fayad L.Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.[J].2009,27(20).
- [21]Zambruno G,Borradori L.Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.[J].2008,128(12).
- [22]Huang, Amy,Madan, Raman K.,Levitt, Jacob.Future therapies for pemphigus vulgaris: Rituximab and beyond[J].2016,74(4).
- [23]Carolyn M Cheney,Deborah M Stephens,Xiaokui Mo,etc.Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia[J].2014,6(3).